October 25, 2019 07:18 AM EDT
Financing

A tale of two IPOs (plus one): Ca­balet­ta prices well be­low range for $75M while Phath­om bags $182M

Amber Tong

When Ca­balet­ta Bio and Phath­om Phar­ma­ceu­ti­cals pen­ciled in $100 mil­lion IPOs along­side 4D Mol­e­c­u­lar Ther­a­peu­tics back in the be­gin­ning of Oc­to­ber, they ap­peared to be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times